Compare ALRS & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALRS | ODTX |
|---|---|---|
| Founded | 1879 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.7M | 875.1M |
| IPO Year | 2019 | 2026 |
| Metric | ALRS | ODTX |
|---|---|---|
| Price | $32.98 | $17.94 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $25.40 | N/A |
| AVG Volume (30 Days) | 203.9K | ★ 269.4K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $4.68 | N/A |
| P/E Ratio | $37.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.26 | $15.10 |
| 52 Week High | $33.44 | $20.00 |
| Indicator | ALRS | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 50.19 |
| Support Level | $30.13 | $17.38 |
| Resistance Level | N/A | $19.60 |
| Average True Range (ATR) | 0.68 | 1.41 |
| MACD | 0.05 | 0.19 |
| Stochastic Oscillator | 91.17 | 67.93 |
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.